Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma

Key facts

Sponsor

Toronto Sunnybrook Regional Cancer Centre

Principal Investigator

Rena Buckstein, MD, MD

Toronto Sunnybrook Regional Cancer Centre

Intervention

alemtuzumab(biological)

Enrollment

84 enrolled

Eligibility

18 years · All sexes

Timeline

2006

Study locations (5)

• St. Paul's Hospital at Providence Health Care - Vancouver, Vancouver, British Columbia, Canada
• Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
• London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
• Odette Cancer Centre at Sunnybrook, Toronto, Ontario, Canada
• Princess Margaret Hospital, Toronto, Ontario, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adult T-cell leukemia/lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT05745714
  HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
  Princess Maxima Center for Pediatric Oncology
• RECRUITINGPHASE2NCT07159620
  Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
  The First Affiliated Hospital of Soochow University
• RECRUITINGPHASE1NCT07108868
  A Phase I Dose Finding Study of MB-CART2219.1
  University Hospital Tuebingen
• RECRUITINGNCT05237986
  Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
  National Cancer Institute (NCI)
• RECRUITINGPHASE1, PHASE2NCT07008885
  BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
  Chinese PLA General Hospital
• ACTIVE NOT RECRUITINGPHASE3NCT07541755
  PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL
  Fujian Medical University Union Hospital
• RECRUITINGPHASE2NCT06698003
  A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
  Memorial Sloan Kettering Cancer Center
• RECRUITINGPHASE2NCT06598722
  BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.
  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

See all trials for Adult T-cell leukemia/lymphoma →